Dulera (mometasone/formoterol) / Merck (MSD), Novartis 
Welcome,         Profile    Billing    Logout  
 9 Diseases   1 Trial   1 Trial   136 News 


12»
  • ||||||||||  Journal:  Drugs for asthma. (Pubmed Central) -  Nov 19, 2024   
    No abstract available No abstract available
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Utilization of Single Maintenance and Reliever Therapy (SMART) for Moderate and Severe Asthma (San Diego Convention Center, Room 28A-B (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_7117;    
    Patients with private insurance may be more likely to be prescribed SMART than patients with public insurance. Providers may be more likely to prescribe SMART to patients using ICS-formoterol as a controller inhaler compared to other controllers, and these patients may be more open to a SMART prescription.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    New Onset Severe Asthma in a College Student? (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6343;    
    At time of referral was being treated with mometasone/formoterol 200/5mcg and as needed albuterol...They were placed on a fluticasone furoate/umeclidinium/vilanterol 200/62...Many patients find that their symptoms respond poorly to standard asthma medications. There are limited reports of anticholinergic therapies in RADS and our success may prove helpful for other clinicians.
  • ||||||||||  Remicade (infliximab) / J&J, Dulera (mometasone/formoterol) / Merck (MSD), Novartis, Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
    Pan-positive PET-CT - Metastasis or Multisystem Sarcoidosis? (San Diego Convention Center, Area D (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6244;    
    The patient subsequently had gradual onset of sarcoid arthropathy, worsened with cold exposure and is being considered for hydroxychloroquine...This patient displayed a constellation of unusual findings due to sarcoidosis, including multiple lesions mimicking metastatic neoplasm, diffuse splenic involvement, and hypercalciuria and nephrolithiasis without hypercalcemia. Biopsy is vital for accurate diagnosis and timely management of sarcoidosis.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Chronic Cough and Paroxysmal Exacerbations of Dyspnea and Hypoxemia: A Case of Allergic Bronchopulmonary Mycosis Due to Penicillium in a Child (San Diego Convention Center, Area J (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_1831;    
    There was questionable improvement on medium-dose inhaled mometasone/formoterol, albuterol, and systemic corticosteroids...Our diagnosis is based on clinical symptoms, evidence of peripheral and airway allergic inflammation, markedly elevated total IgE, Penicillium-specific IgG and IgE, and isolated Penicillium in BAL fluid and the home environment. Penicillium is a possible cause of ABPM in children and should be considered in treatment-refractory chronic cough.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Trial completion date, Trial primary completion date:  Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma (clinicaltrials.gov) -  Oct 26, 2023   
    P=N/A,  N=60, Recruiting, 
    Penicillium is a possible cause of ABPM in children and should be considered in treatment-refractory chronic cough. Trial completion date: Jun 2022 --> Jun 2027 | Trial primary completion date: Jun 2022 --> Jun 2027
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Trial completion:  Replication of the P04334 Asthma Trial in Healthcare Claims Data (clinicaltrials.gov) -  Jul 27, 2023   
    P=N/A,  N=10288, Completed, 
    Trial completion date: Jun 2022 --> Jun 2027 | Trial primary completion date: Jun 2022 --> Jun 2027 Active, not recruiting --> Completed
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Asthma With Pneumonia Secondary to Influenza (Walter E. Washington Convention Center, Area E, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_8184;    
    Dulera and prednisone 40 mg for 5 days treated the asthma...Estimating Influenza-associated deaths in the United States. AJPH 2009;99:S225-S230.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    A 12 Year Old Male in Drug Induced Adrenal Crisis (Area B, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_4662;    
    He had received multiple courses of oral prednisone for asthma exacerbations earlier in his lifetime...Altered mental state resolved after initial steroid dose was given, and IV hydrocortisone (50 mg/5mL) was maintained every 6 hours during admission...Secondary AI in relation to chronic, high-dose ICS therapy is caused by the suppression of the hypothalamic-pituitary-adrenal function. Detailing patient history and medication usage are vital in distinguishing the types of AI.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Review, Journal:  A Practical Guide to Implementing SMART in asthma management. (Pubmed Central) -  Feb 10, 2022   
    The SMART regimen should be introduced with a careful explanation of its role in self-management and preferably with a customized written asthma action plan. The cost to patients and availability of SMART treatment will depend on prescribed dose and national/local payer agreements.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Journal:  A 56-Year-Old Man With Emphysema, Rash, and Arthralgia. (Pubmed Central) -  Jan 14, 2022   
    Based on pulmonary function tests from an outside provider, he had received a diagnosis of exercise-induced asthma and had been prescribed an albuterol inhaler to use on an as-needed basis, which failed to improve his symptoms. He was later prescribed a mometasone-formoterol inhaler, still with no symptomatic improvement.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis, Nucala (mepolizumab) / GSK
    [VIRTUAL] Diagnostic Dilemma: EGPA Without Vasculitis on Biopsy? () -  Mar 14, 2021 - Abstract #ATS2021ATS_2019;    
    She was started on a mometasone-formoterol inhaler, fluticasone nasal spray, and prednisone at 40 mg/day...She was discharged on a prednisone taper with plans for initiation of mepolizumab, an IL-5 inhibitor...Presence of systemic signs ruled out other entities such as eosinophilic pneumonia, allergic bronchopulmonary aspergillosis and aspirin-exacerbated respiratory disease. In conclusion, one should not overlook the diagnosis of EGPA with lack of ANCA and vasculitis.
  • ||||||||||  fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
    [VIRTUAL] A retrospective review of an inhaler to nebulizer therapeutic interchange program across a health system () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_1750;    
    The primary outcome measure is to assess the percent of albuterol/ipratropium and ICS/LABA inhalers therapeutically interchanged. Secondary outcomes include assessment of readmission rates (all cause 30-day readmission and respiratory related 30-day readmission), the percentage of patients discharged with the appropriate inhaler, and a financial analysis of the implementation of the therapeutic interchange.
  • ||||||||||  Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
    Possible Low-Value Medication Use by Persons with Idiopathic Pulmonary Fibrosis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area K) -  Mar 15, 2020 - Abstract #ATS2020ATS_9137;    
    One hundred seventeen (117, 28%) persons were first treated with a proton pump inhibitor following IPF diagnosis. Two hundred eleven (211, 50%) persons used a SABA.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Trial primary completion date:  Personalized Treatment Algorithms for Difficult-to-treat Asthma (clinicaltrials.gov) -  Mar 9, 2020   
    P2,  N=21, Completed, 
    Two hundred eleven (211, 50%) persons used a SABA. Trial primary completion date: Dec 2018 --> Oct 2019
  • ||||||||||  Bevespi Aerosphere (glycopyrrolate and formoterol) / AstraZeneca
    DUAL-COMBINATION MAINTENANCE INHALER PREFERENCES IN ASTHMA AND COPD: A PATIENT-CENTERED BENEFIT-RISK ASSESSMENT (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_2340;    
    Mometasone/formoterol pMDI and budesonide/formoterol pMDI were the preferred higher-dose ICS/LABA inhalers for patients with asthma. Tiotropium/olodaterol soft mist inhaler was the preferred LAMA/LABA inhaler for patients with COPD.Clinical Implications:Patient preferences for maintenance inhaler attributes can be used to identify which maintenance inhalers within each treatment class patients prefer.
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Trial completion date, Trial primary completion date:  Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma (clinicaltrials.gov) -  Aug 20, 2019   
    P=N/A,  N=60, Recruiting, 
    Tiotropium/olodaterol soft mist inhaler was the preferred LAMA/LABA inhaler for patients with COPD.Clinical Implications:Patient preferences for maintenance inhaler attributes can be used to identify which maintenance inhalers within each treatment class patients prefer. Trial completion date: Jun 2018 --> Jun 2022 | Trial primary completion date: Jun 2018 --> Jun 2022
  • ||||||||||  Dulera (mometasone/formoterol) / Merck (MSD), Novartis
    Trial completion date, Trial initiation date, Trial primary completion date, Real-world evidence, Adherence, Real-world:  Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence (clinicaltrials.gov) -  Feb 23, 2018   
    P4,  N=40, Completed, 
    Trial completion date: Jun 2018 --> Jun 2022 | Trial primary completion date: Jun 2018 --> Jun 2022 Trial primary completion date: Dec 2015 --> Jul 2017 | Trial completion date: Dec 2015 --> Jul 2017 | Initiation date: Jan 2014 --> Mar 2014